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are-Metal Stent Implantation in Patients with
T-Segment Elevation Myocardial Infarction
cute and 9-Month Intravascular Ultrasound Results of the
ISSION! Intervention Study
as L. van der Hoeven, MD,* Su-San Liem, MD,* Jouke Dijkstra, MSC,†
andrin C. Bergheanu, MD,* Hein Putter, MSC,‡ M. Louisa Antoni, MD,*
ouwe E. Atsma, MD,* Marianne Bootsma, MD,* Katja Zeppenfeld, MD,*
. Wouter Jukema, MD,* Martin J. Schalij, MD*
eiden, the Netherlands
bjectives Acute and late stent malapposition (SM) after bare-metal stents (BMS) and sirolimus-
luting stents (SES) in ST-segment elevation myocardial infarction patients were studied.
ackground Stent thrombosis may be caused by SM after primary percutaneous coronary interven-
ion in ST-segment elevation myocardial infarction patients.
ethods Post-procedure and follow-up intravascular ultrasound data were available in 184 out of
10 patients (60%; 104 SES, 80 BMS) included in the MISSION! Intervention Study. To determine the
ontribution of remodeling and changes in plaque burden to the change in lumen cross-sectional
rea (CSA) at SM sites, the change in lumen CSA (follow-up minus post-lumen CSA) was related to
he change in external elastic membrane CSA (remodeling) and change in plaque and media CSA
plaque burden).
esults Acute SM was found in 38.5% SES patients and 33.8% BMS patients (p  0.51), late SM in
7.5% SES patients and 12.5% BMS patients (p  0.001). Acquired SM was found in 25.0% SES patients
nd 5.0% BMS patients (p  0.001). Predictors of acute SM were reference diameter (SES: odds ratio [OR]
.49, 95% conﬁdence interval [CI] 1.29 to 9.43; BMS: OR 28.8, 95% CI 4.25 to 94.5) and balloon pressure
BMS: OR 0.74, 95% CI 0.58 to 0.94). Predictors of late SM were diabetes mellitus (SES: OR 0.16, 95% CI
.02 to 1.35), reference diameter (BMS: OR 19.2, 95% CI 2.64 to 139.7), and maximum balloon pressure
BMS: OR 0.74, 95% CI 0.55 to 1.00). Change in lumen CSA was related to change in external elastic
embrane CSA (R  0.73, 95% CI 0.62 to 0.84) after SES implantation and to change in plaque and me-
ia CSA (R  0.62, 95% CI 0.77 to 0.46) after BMS implantation. After SES implantation, acquired
M was caused by positive remodeling in 84% and plaque reduction in 16% of patients.
onclusions Acute SM was common after SES and BMS stent implantation in ST-segment elevation
yocardial infarction patients. After SES implantation, late acquired SM is common and generally
aused by positive remodeling. (The MISSION! Intervention Study, ISRCTN62825862) (J Am Coll
ardiol Intv 2008;1:192–201) © 2008 by the American College of Cardiology Foundation
rom the *Department of Cardiology, †Department of Medical Statistics and Bio-Informatics, and ‡Department of Radiology,
ivision of Image Processing, Leiden University Medical Center, Leiden, the Netherlands. Supported by the Netherlands Heart
oundation and by an unrestricted research grant from Guidant Inc., Nieuwegein, the Netherlands. Dr. Jukema is an established
linical investigator of the Netherlands Heart Foundation (Grant 2001D032).anuscript received December 10, 2007; revised manuscript received January 31, 2008, accepted February 7, 2008.
A
s
m
D
s
m
f
m
p
p
fi
p
e
t
s
s
i
b
p
S
t
i
i
d
i
S
I
e
b
M
P
t
i
(
B
S
t
c
c
i
i
9
i
m
B
s
a
S
y
t
e
t
b
o
l
w
t
s
S
p
6
i

5
a
s
u
e
a
a
j
I
a
u
I
s
p
a
p
s
w
m
d
t
2
d
E
C
a
q
3
g
w
1
b
i
g
3
a
Q
o
c
c
A
s
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 1 , N O . 2 , 2 0 0 8
A P R I L 2 0 0 8 : 1 9 2 – 2 0 1
van der Hoeven et al.
Stent Malapposition After SES and BMS in STEMI Patients
193lthough long-term angiographic results of drug-eluting
tents (DES) are superior to the results obtained with bare-
etal stents (BMS), the safety of DES became a major issue as
ES are associated with an increased risk of late or very late
tent thrombosis (1–3). It is difficult to determine the exact
echanism of stent thrombosis in individual patients. Renal
ailure, diabetes mellitus, stent implantation during acute
yocardial infarction, insufficient antithrombotic therapy or
remature discontinuation of dual antiplatelet therapy, im-
lanted stent length, or bifurcation stenting have been identi-
ed as risk factors of stent thrombosis (1,2,4,5). From a
athological point of view, drug-induced delayed re-
ndothelialization of the endothelium seems to play an impor-
ant role (6). Another factor associated with stent thrombosis is
tent malapposition (SM) (7,8). Stent malapposition may be a
ign of impaired healing or the result of suboptimal stent
mplantation. Stent malapposition may increase the throm-
otic risk due to the presence of intraluminal stent struts. In
atients with stable angina, several studies reported increased
M rates in DES-treated patients compared with BMS-
reated patients (9,10). Limited data are reported about the
ncidence and mechanisms of SM after percutaneous coronary
nterventions in patients with ST-segment elevation myocar-
ial infarction (STEMI) (11). This study reports on the
ncidence of acute and late SM within the Medical Image
haring with Satellite Integrated Optical-Fiber Network
ntervention Study, a randomized study comparing the
fficacy of DES with BMS in STEMI patients, as studied
y intravascular ultrasound imaging (IVUS).
ethods
atient selection and randomization. The MISSION! In-
ervention Study was a single-center, single-blind, random-
zed controlled trial comparing sirolimus-eluting stents
SES) (Cypher, Cordis Corp., Miami Lakes, Florida) and
MS (Vision, Guidant Corp., Indianapolis, Indiana) in
TEMI patients. The study was approved by the Institu-
ional Ethical Review Board. All patients gave informed
onsent before the procedure. An additional informed
onsent was obtained for follow-up angiography and IVUS
maging at 9 months. This study is a predefined substudy
ncluding patients in whom both post-procedural and
-month IVUS results were available. The study design,
nclusion and exclusion criteria, end point definition, and
ain outcomes of the study were published previously (12).
riefly, patients were eligible for participation if they had
ymptoms of acute myocardial infarction9 h before arrival
t the catheterization laboratory and the ECG revealed a
TEMI. Key exclusion criteria included age 18 or 80
ears; the presence of a left main lesion of 50% stenosis;
riple vessel disease, defined as 50% stenosis in 3 major
picardial vessels; previous percutaneous coronary interven-
ion or bypass grafting of the culprit vessel; failed throm- tolytic therapy for the index infarction; reference diameter
f the culprit lesion of 2.25 or 3.75 mm; and lesion
ength 24 mm. After successful positioning of the guide-
ire distal to the target lesion, patients were randomized to
reatment with BMS or SES. The primary end point of the
tudy was angiographic in-segment late loss at 9 months.
tudy procedure and adjunct medication. Before the index
rocedure, all patients received 300 mg of aspirin, 300 to
00 mg of clopidogrel, and an intravenous bolus of abcix-
mab (25 g/kg), followed by a continuous infusion of 10
g/kg/min for 12 h. At the beginning of the procedure,
,000 IU of heparin were given. Lesions were treated
ccording to current interventional practice. If more than 1
tent was required, additional assigned study stents were
sed. Stent size and length selection was based on visual
stimation. Before and immedi-
tely after the intervention, 2
ngiograms in orthogonal pro-
ections were obtained. The
VUS imaging was performed
fter stent implantation to doc-
ment the angiographic result.
ntravascular ultrasound-guided
tent implantation was not
erformed to reflect routine
ngiography-guided stent im-
lantation. Intravascular ultra-
ound imaging was performed
ith motorized pullback (0.5
m/s) starting at least 10 mm
istal to the stent and ending at
he coronary ostium, using a
.9-F 20-MHz catheter and a
edicated IVUS console (Eagle
ye, Volcano Corp., Rancho
ordova, California) (13). Each
ngiogram and ultrasound se-
uence was preceded by 200 to
00 g of intracoronary nitro-
lycerin. After the procedure, aspirin (80 to 100 mg/day)
as prescribed indefinitely and clopidogrel (75 mg/day) for
2 months. During follow-up, patients were treated with
eta-blockers, statins, and angiotensin-converting enzyme
nhibitors or angiotension II-blockers, according to current
uidelines (14). Patients were seen at the outpatient clinic at
0 days and 3, 6, and 12 months. Follow-up angiography
nd IVUS imaging was performed at 9 months.
uantitative coronary angiography. Coronary angiograms
btained at baseline, after completion of the stenting pro-
edure, and at the 9-month follow-up were digitally re-
orded and analyzed blinded for the assigned treatment.
nalyses were performed with automated edge-detection
oftware (CMS version 6.0, Medis Medical Imaging Sys-
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CI  confidence interval
CSA  cross-sectional area
DES  drug-eluting stent(s)
EEM  external elastic
membrane
IVUS  intravascular
ultrasound
LBS  lumen behind stent
OR  odds ratio
P&M  plaque and media
SES  sirolimus-eluting
stent(s)
SM  stent malapposition
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarctionems, Leiden, the Netherlands) at the worst view projection
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19415). The stented zone and the proximal and distal 5-mm
tent edges were evaluated. The reference diameter was
etermined by interpolation. Within the stented segment,
inimum luminal diameter and percentage diameter steno-
is were determined. The percentage diameter stenosis was
efined as the difference between reference and actual
iameter divided by the reference diameter and multiplied
y 100. Late loss was defined as the difference between the
ost-procedural and follow-up minimum luminal diameter.
VUS analysis. IVUS images were analyzed offline, using
uantitative IVUS analysis software (QCU-CMS 4.14,
edis, Leiden, the Netherlands) (16). Analyses were per-
ormed by 2 experienced analysts blinded for the assigned
reatment. A SM was defined as a separation of at least 1
tent strut from the intimal surface that was not overlapping
side branch and had IVUS evidence of blood speckles
ehind the strut (17). A SM was defined as acute if present
mmediately after the index procedure, as late if present at
he 9-month follow-up, as resolved if present after stent
mplantation but not at follow-up, as persistent if present
oth after stent implantation and at follow-up, and as
cquired if present at follow-up but not after stent implan-
ation. The identification of SM sites in post-procedural
mages was performed independently from follow-up im-
ges. Hereafter, the post-procedural IVUS images were
ompared side by side with the follow-up images to deter-
ine whether the SM resolved, persisted, or was acquired.
orresponding post-procedural and follow-up images at the
ite of maximum lumen area behind the stent were selected.
he external elastic membrane (EEM) cross-sectional area
CSA), stent CSA, lumen CSA inside the stent, and lumen
SA (inside and outside the stent) were determined in
elected frames (Fig. 1). Furthermore, the maximum arc of
M, the maximum depth of the lumen behind the stent
LBS) and the maximum calcium arc at the site of SM were
etermined. The LBS CSA was calculated by subtracting
he lumen CSA inside the stent from the lumen CSA. The
Figure 1. IVUS Contours and Measurements
Schematic diagram illustrating intravascular ultrasound (IVUS) contours and
measurements.eointimal CSA was calculated by subtracting the lumenSA inside the stent from the stent CSA. Plaque burden
as defined as the plaque plus media (P&M) CSA and was
alculated by subtracting the lumen CSA from the EEM
SA. Percentage plaque burden was calculated by dividing
he P&M CSA by the EEM CSA and multiplying by
00%. Vessel remodeling was calculated by follow-up minus
ost-procedure EEM CSA (EEM CSA). Positive remod-
ling was defined as an increase in EEM CSA and negative
emodeling as a decrease in EEM CSA. Change () in
laque burden was calculated by follow-up minus post-
rocedure P&M CSA (P&M CSA). Plaque increase was
efined as an increase and plaque reduction as a decrease of
he P&M CSA.
tatistical analysis. Statistical analysis was conducted with
PSS 12.0.1 statistical analysis software (SPSS Inc., Chi-
ago, Illinois). Categorical variables are presented as number
%) and continuous variables as mean  standard deviation.
nalysis of post-procedural and follow-up angiographic and
VUS data was conducted according to the number of
atients for which complete data were available. Continuous
ariables were compared between the treatment groups with
t test or, in case of non-normality, with an equivalent
onparametric test. Categorical variables were compared
ith chi-square test or Fisher exact test. The correlation
etween variables was calculated using the Pearson product
oment correlation method. Multivariate logistic regres-
Table 1. Baseline Clinical and Angiographic Characteristics
Characteristic
SES
(n  104)
BMS
(n  80) p Value
Age (yrs) 58.6 11.5 58.9 11.8 0.84
Male gender (%) 76 (73.1) 65 (81.3) 0.19
Diabetes mellitus (%) 10 (9.6) 3 (3.8) 0.12
Current smoker (%) 62 (59.6) 41 (51.3) 0.28
Hypercholesterolemia (%) 22 (21.2) 11 (13.8) 0.19
Hypertension (%) 36 (34.6) 22 (27.5) 0.30
Family history of CAD (%) 45 (43.3) 26 (32.5) 0.14
Prior myocardial infarction (%) 5 (4.8) 3 (3.8) 1.00
Prior PCI or CABG (%) 2 (1.9) 1 (1.3) 1.00
Target vessel (%)
LAD 60 (57.7) 48 (60.0) 0.15
RCA 25 (24.0) 25 (31.3)
LCX 19 (18.3) 7 (8.7)
Multivessel disease (%) 37 (35.6) 28 (35.0) 0.94
TIMI ﬂow grade (%)
0–1 73 (70.2) 56 (70.0) 0.98
2–3 31 (29.8) 24 (30.0)
Vessel reference diameter (mm) 2.81  0.56 2.93  0.55 0.16
Minimal luminal diameter (mm) 0.23  0.36 0.23  0.38 0.96
Diameter stenosis (%) 92.0  12.4 92.6  12.0 0.74
BMS  bare-metal stent; CABG  coronary artery bypass graft; CAD  coronary artery disease;
LAD  left anterior descending; LCX  left circumflex (artery); PCI  percutaneous coronary
intervention; RCA right coronary artery; SES sirolimus-eluting stent; TIMI Thrombolysis InMyocardial Infarction.
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195ion analysis was performed to determine independent
linical, angiographic, and procedural predictors of acute,
ate, and acquired SM by entering all univariate predictors
p  0.10) in the model. The variables analyzed in the
odel were assigned stent type, gender, diabetes mellitus,
aseline Thrombolysis In Myocardial Infarction (TIMI)
ow, pre-dilation, implanted stent length, maximal balloon
ressure, balloon-to-artery ratio, vessel reference diameter,
ost-procedural percentage diameter stenosis, and the in-
eraction of these variables with the assigned stent type. All
values were 2-sided, and a p value 0.05 was considered
tatistically significant.
esults
atients. Patient and angiographic characteristics are sum-
Table 2. Clinical, Angiographic, and Procedural Correlates of SM After SES
Acute (Post-Procedur
SM
No. of patients (%) 40 (38.5) 6
Clinical characteristics
Male gender (%) 31 (77.5) 4
Age (yrs) 58.7 11.3 58
Diabetes mellitus (%) 4 (10.0)
Angiographic characteristics
Target vessel (%)
LAD 28 (70.0) 3
RCA 7 (17.5) 1
LCX 5 (12.5) 1
Multivessel disease (%) 11 (27.5) 2
TIMI ﬂow grade 0 or 1 at baseline (%) 24 (60.0) 4
Vessel reference diameter
Post-procedure (mm) 3.16 0.41 2.9
Minimal luminal diameter (mm)
Baseline 0.26 0.35 0.2
Post-procedure 2.81 0.37 2.5
Diameter stenosis post-procedure (%) 10.8 5.8 10
Late luminal loss at follow-up (mm)
Proximal edge 0.11 0.35 0.2
In-stent 0.09 0.25 0.1
Distal edge 0.040.34 0.0
Procedural characteristics
Direct stenting (%) 18 (45.0) 2
No. of stents implanted 1.30 0.56 1.2
Implanted stent length (mm) 24.8 11.7 26
Post-dilatation (%) 17 (42.5) 2
Maximum balloon diameter (mm) 3.49 0.27 3.3
Maximal balloon pressure (atm) 12.8 2.4 12
Maximal balloon to artery ratio 1.18 0.17 1.1
*Comparison of acquired versus no SM at follow-up. †p 0.05
SM stent malapposition; other abbreviations as in Table 1.arized in Table 1. Of 310 patients included in the 2ISSION! Intervention Study, follow-up angiography was
erformed in 254 patients (84%). Post-procedural and
ollow-up IVUS image loops qualified for quantitative
nalysis of the stent, lumen, and SM evaluation in 184
atients (60%). Clinical, angiographic, and procedural cor-
elates of acute and late SM in these patients are listed in
able 2 for SES and Table 3 for BMS. Within these 184
atients, 129 SM sites were identified and analyzed (Table
). Three sites were not analyzable because of severe
alcification.
cute SM. Acute SM was found in 40 out of 104 (49 sites)
ES patients (38.5%) and in 27 out of 80 (32 sites) BMS
atients (33.8%) (p  0.51). Univariate predictors of acute
M after SES implantation were vessel reference diameter
odds ratio [OR] 3.68, 95% confidence interval [CI] 1.38 to
.81; p  0.009) and baseline TIMI flow grade 2 or 3 (OR
ntation (n 104)
Late (Follow-Up)
SM No SM Acquired SM*
) 39 (37.5) 65 (62.5) 26 (25.0)
) 29 (74.4) 47 (72.3) 21 (80.8)
.7 59.6 10.2 57.9 12.3 60.1 9.2
1 (2.6) 9 (13.8) 0 (0.0)†
) 22 (56.4) 38 (58.5) 11 (42.3)
) 9 (23.1) 16 (24.6) 7 (26.9)
) 8 (20.5) 11 (16.9) 8 (30.8)
) 16 (41.0) 21 (32.3) 11 (42.3)
) 28 (71.8) 45 (69.2) 19 (73.1)
8† 3.05 0.45 2.97 0.48 3.11 0.50
7 0.22 0.34 0.24 0.38 0.24 0.39
0† 2.74 0.39 2.64 0.41 2.83 0.39
9.7 7.1 10.9 6.8 8.5 6.9
9 0.15 0.34 0.19 0.31 0.24 0.35
7 0.13 0.26 0.15 0.27 0.15 0.31
1 0.07 0.33 0.05 0.31 0.08 0.35
) 16 (41.0) 26 (40.0) 11 (42.3)
2 1.33 0.62 1.26 0.48 1.31 0.62
.3 27.2 12.2 24.5 10.9 26.8 10.8
) 15 (38.5) 25 (38.5) 11 (42.3)
9† 3.42 0.24 3.38 0.31 3.42 0.23
12.8 2.1 12.4 2.3 13.2 2.1
9 1.16 0.17 1.19 0.18 1.14 0.19Impla
e)
No SM
4 (61.5
5 (70.3
.5 11
6 (9.4)
2 (50.0
8 (28.1
4 (21.9
6 (40.6
9 (76.6
0 0.4
1 0.3
9 0.4
.2 7.6
2 0.2
8 0.2
3 0.3
4 (37.5
8 0.5
.0 11
3 (35.9
4 0.2
.4 2.2
8 0.1.18, 95% CI 0.92 to 5.13; p  0.08). After BMS
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196mplantation, univariate predictors of acute SM were vessel
eference diameter (OR 20.1, 95% CI 4.39 to 92.4; p 
.001), maximum balloon pressure (OR 0.84, 95% CI 0.69
o 1.02; p  0.08), and balloon-to-artery ratio (OR 0.03,
5% CI 0.00 to 0.71; p  0.03). Multivariate predictors of
cute SM were vessel reference diameter (OR 3.49, 95% CI
.29 to 9.43; p  0.01) after SES implantation and vessel
eference diameter (OR 28.8, 95% CI 4.25 to 94.5; p 
.001) and maximum balloon pressure (OR 0.74, 95% CI
.58 to 0.94; p  0.01) after BMS implantation.
Stent malapposition persisted in 19 out of 40 (28 sites)
ES patients (48%) compared with 9 out of 27 (11 sites)
MS patients (33%) (p 0.15). In the remaining acute SM
atients, SM resolved (although in 3 SES patients acute SM
esolved, but late SM developed at another site). Compared
ith resolved SES SM sites, persistent SES SM sites had
Table 3. Clinical, Angiographic, and Procedural Correlates of SM After BM
Acute (Post-Procedure
SM No
No. of patients (%) 27 (33.8) 53
Clinical characteristics
Male gender (%) 21 (77.8) 44
Age (yrs) 61.4 12.4 57.7
Diabetes mellitus (%) 1 (3.7) 2
Angiographic characteristics
Target vessel (%)
LAD 15 (55.6) 33
RCA 9 (33.3) 16
LCX 3 (11.1) 4
Multivessel disease (%) 10 (37.0) 18
TIMI ﬂow grade 0 or 1 at baseline (%) 17 (63.0) 39
Vessel reference diameter
Post-procedure (mm) 3.39 0.37 2.95
Minimal luminal diameter (mm)
Baseline 0.33 0.51 0.17
Post-procedure 2.94 0.31 2.62
Diameter stenosis post-procedure (%) 13.2 7.4 10.7
Late luminal loss at follow-up (mm)
Proximal edge 0.40 0.60 0.28
In-stent 1.01 0.51 0.81
Distal edge 0.10 0.48 0.16
Procedural characteristics
Direct stenting (%) 9 (33.3) 24
No. of stents implanted 1.41 0.50 1.32
Implanted stent length (mm) 27.7 10.2 26.0
Post-dilatation (%) 11 (40.7) 13
Maximum balloon diameter (mm) 3.54 0.24 3.39
Maximal balloon pressure (atm) 11.6 2.8 12.6
Maximal balloon to artery ratio 1.09 0.21 1.19
*Only the mean value is presented because of low numbers. No statistical comparison was perform
Abbreviations as in Tables 1 and 2.arger LBS CSA (2.7 vs. 1.6 mm2, p  0.005), larger depth if the LBS (0.69 vs. 0.48 mm, p  0.02), and larger arc of
he LBS (166° vs. 135°, p  0.04) and were located at sites
ith more plaque burden (49% vs. 44%, p  0.04).
ersistent BMS SM sites had a larger depth of the LBS
0.71 vs. 0.51 mm, p  0.02) and were located at sites with
arger EEM CSA (24.0 vs. 19.6 mm2, p  0.01) and P&M
SA (12.0 vs. 8.8 mm2, p  0.007) than the resolved BMS
M sites. Moreover, these sites demonstrated less negative
emodeling (EEM CSA: 0.7 vs. 1.1 mm2, p  0.001)
nd less increase in P&M CSA (P&M CSA: 1.1 vs. 3.0
m2, p  0.003).
ate SM. At the 9-month follow-up, late SM was ob-
erved in 39 of 104 (73 sites) SES patients (37.5%) and in
0 of 80 (14 sites) BMS patients (12.5%, p  0.001).
esides persistent SM, acquired SM at 9 months was
ommon after SES implantation but rare after BMS
lantation (n  80)
Late (Follow-Up)
SM No SM Acquired SM*
10 (12.5) 70 (87.5) 4 (5.0)
9 (90.0) 56 (80.0) 4 (100.0)
63.3 11.0 58.3 11.9 66.0
0 (0.0) 3 (4.3) 0 (0.0)
5 (50.0) 43 (61.4) 1 (25.0)
4 (40.0) 21 (30.0) 3 (75.0)
1 (10.0) 6 (8.6) 0 (0.0)
4 (40.0) 24 (34.3) 1 (25.0)
5 (50.0) 51 (72.9) 1 (25.0)
† 3.48 0.39 3.04 0.42† 3.43
0.52 0.66 0.18 0.31 0.98
† 2.94 0.26 2.70 0.36† 3.04
15.2 7.2 11.0 7.9 11.0
0.28 0.35 0.33 0.51 0.20
0.84 0.41 0.89 0.45 0.69
0.08 0.33 0.17 0.46 0.06
4 (40.0) 29 (41.4) 3 (75.0)
1.40 0.52 1.34 0.56 1.00
28.5 10.7 26.3 10.5 23.0
3 (30.0) 21 (30.0) 0 (0.0)
† 3.55 0.16 3.42 0.29 3.50
11.0 2.6 12.4 2.4 11.0
1.09 0.24 1.16 0.17 1.03
 0.05.S Imp
)
SM
(66.2)
(83.0)
 11.4
(3.8)
(62.3)
(30.2)
(7.5)
(34.0)
(73.6)
 0.39
 0.28
 0.33
 8.1
 0.41
 0.39
 0.45
(45.3)
 0.58
 10.7
(24.5)
 0.29
 2.3
 0.15
ed. †pmplantation (26 of 104 vs. 4 of 80 patients, 25.0% vs.
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197.0%; p  0.001). The only predictor of acquired SM was
ssigned SES stent (OR 9.43, 95% CI 2.73 to 32.6; p 
.001). Diabetes mellitus was associated with a lower rate
f late SM after SES implantation (OR 0.16, 95% CI
.02 to 1.35; p  0.09). Univariate predictors of late SM
fter BMS implantation were vessel reference diameter
OR 15.3, 95% CI 2.20 to 106.1; p  0.006) and
aximum balloon pressure (OR 0.79, 95% CI 0.60 to
.04; p  0.10). Multivariate predictors of late SM after
MS implantation were vessel reference diameter (OR
9.2, 95% CI 2.64 to 139.7; p  0.004) and maximum
alloon pressure (OR 0.74, 95% CI 0.55 to 1.00; p 
.05). There was no relation between the presence and
rc of calcium and the persistence of acute SM or the
evelopment of acquired SM.
echanism of lumen CSA change. The EEM CSA (pos-
Table 4. IVUS Characteristics of Resolved, Persistent, and Acquired SM Si
Characteristics
Resolved
SES BMS p Value SE
No. of SM sites 21 21 2
LBS CSA (mm2) 0.32
Post-procedure 1.6 0.7 1.9 1.3 2.7
Follow-up 2.5
LBS length (mm) 0.68
Post-procedure 1.4 1.0 1.6 1.6 1.5
Follow-up 1.3
LBS maximum depth (mm) 0.59
Post-procedure 0.48 0.16 0.51 0.21 0.69
Follow-up 0.69
LBS arc (°) 0.33
Post-procedure 135 37 150 60 166
Follow-up 171
Calcium (%) 4 (19) 4 (19) 1.00 9 (
Stent CSA (mm2) 8.9 1.4 8.8 1.5 0.83 8.1
Plaque burden (%) 44 8 44 7 0.90 49
Lumen CSA (mm2)
Post-procedure 10.5 1.7 10.8 2.4 0.65 10.8
Follow-up 8.6 1.5 6.6 1.6 0.001 10.7
∆Lumen CSA (mm2) 1.9 0.7 4.1 1.9 0.001 0.2
EEM CSA (mm2)
Post-procedure 19.1 4.3 19.6 4.6 0.71 21.3
Follow-up 18.3 3.9 18.5 4.0 0.86 21.1
∆EEM CSA 0.8 1.5 1.1 1.2 0.49 0.2
P&M CSA (mm2)
Post-procedure 8.6 3.3 8.8 2.8 0.82 10.5
Follow-up 9.6 3.0 11.8 3.3 0.03 10.4
∆P&M CSA 1.0 1.6 3.0 1.5 0.001 0.1
Neointima CSA (mm2) 0.2 0.3 2.0 1.2 0.001 0.1
*Only the mean is presented because of low numbers; no statistical comparison was performed. †C
CSA cross-sectional area; EEM external elastic membrane; IVUS intravascular ultrasound; Ltive or negative remodeling) and P&M CSA (plaque (ncrease or reduction) during the follow-up period for each
M site are plotted in Figure 2. After BMS implantation,
lumen CSA was mainly associated with P&M CSA
R  0.62, 95% CI 0.77 to 0.46; p  0.001) and less
ith EEM CSA (R  0.38, 95% CI 0.23 to 0.54; p 
.001) (Fig. 3A). The lumen CSA after SES implantation
as strongly associated with EEM CSA (R  0.73, 95%
I 0.62 to 0.84; p  0.001) and weakly associated with
P&M CSA (R  0.27, 95% CI 0.38 to 0.16; p 
.001) (Fig. 3B). Examples of the relation between lumen
SA with EEM CSA and P&M CSA are given in
igure 4. The dominant mechanism of development of
cquired SM after SES implantation (45 sites) was positive
emodeling in 38 sites (84%) and plaque reduction in 7 sites
16%). Compared to sites with positive remodeling, plaque
eduction sites were located at sites with larger stent CSA
fter SES and BMS Implantation
Persistent Acquired p Value†
BMS p Value SES BMS*
SES
R vs. P
BMS
R vs. P
11 45 3
3.2 2.5 0.55 0.005 0.14
4.1 3.0 0.13 3.2 1.7 4.1
2.0 1.8 0.34 0.75 0.47
1.7 1.6 0.44 2.7 2.3 1.2
0.71 0.23 0.86 0.02 0.02
0.77 0.31 0.49 0.69 0.30 0.84
0.04
188 91 0.40 0.23
176 119 0.89 205 71 226
5 (46) 0.79 24 (53) 1 (33) 0.41 0.12
8.9 1.0 0.07 8.2 1.5 9.1 0.09 0.82
50 10 0.64 55 9 64 0.04 0.07
12.0 3.1 0.27 8.2 1.5 9.1 0.58 0.22
11.6 3.9 0.47 11.4 2.2 12.9 0.003 0.002
0.4 1.5 0.65 3.2 1.7 3.9 0.001 0.001
24.0 4.4 0.20 19.0 5.6 25.7 0.17 0.01
24.7 4.6 0.08 21.8 5.3 27.1 0.07 0.001
0.7 1.5 0.04 2.8 2.0 1.4 0.12 0.001
12.0 3.4 0.29 10.8 4.8 16.5 0.10 0.007
13.1 2.8 0.03 10.4 4.0 14.1 0.41 0.29
1.1 1.8 0.04 0.4 1.5 2.4 0.01 0.003
0.7 0.9 0.04 0.0 1.1 0.2 0.28 0.004
ison between resolved (R) and persistent (P) SM sites.
men behind stent; P&M plaque and media; other abbreviations as in Tables 1 and 2.tes A
S
8
1.7
1.8
1.4
1.3
0.36
0.34
64
53
32)
1.7
7
2.9
3.0
1.4
6.3
6.1
1.1
4.2
3.5
1.3
0.2
ompar9.7 vs. 8.0 mm2), larger EEM CSA (26.4 vs. 17.6 mm2,
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198 0.02), larger P&M CSA (16.8 vs. 9.7 mm2, p  0.04)
nd larger plaque burden (61% vs. 54%, p  0.04) contain-
ng less calcium (14% vs. 61%, p  0.04). No differences
ere found between acquired SM sites within the BMS
roup because of limited numbers and lack of statistical
ower.
linical outcome. During 12 months of follow-up, none of
he patients included in this analysis died. Myocardial
nfarction occurred in 3 SES patients and 4 BMS patients,
ll related to revascularization procedures (p  0.47). These
yocardial infarctions were only minimal troponin T leaks.
arget vessel revascularization was performed in 8 BMS
atients and 1 SES patient (p  0.004). Target lesion
evascularization was performed in 6 BMS and 0 SES
atients (p  0.005). None of the patients included in this
tudy experienced stent thrombosis.
iscussion
ey findings of this study were: 1) acute SM was frequently
bserved in SES- and BMS-treated STEMI patients; 2)
ate SM was common after SES implantation, but was also
bserved after BMS implantation; 3) acquired SM occurred
lmost exclusively after SES implantation; 4) the dominant
echanism of lumen change at SM sites during follow-up
as related to vessel remodeling in SES patients and to
Figure 2. Change of EEM and P&M CSA During the Follow-Up Period for Al
(A) Bare-metal stent (BMS); (B) sirolimus-eluting stent (SES). The stent malappo
denotes change (follow-up minus post-procedure). (A) BMS: Most of the acute
increase in the plaque and media (P&M) cross-sectional area (CSA) during the
The external elastic membrane (EEM) and P&M CSA are virtually unchanged in
tive x axis, indicating that positive remodeling (enlargement of the EEM CSA, w
of SM in these sites. In a minority of sites, plaque reduction (decrease of the Phanges in plaque burden in BMS patients; and 5) acquired bM after SES implantation was caused by positive remod-
ling in the majority of cases (84%) and plaque reduction in
limited number of cases (16%).
redictors of acute SM. Acute SM occurs at a similar rate
fter SES (38.5%) and BMS (33.8%) implantation in
TEMI patients. In patients with stable angina, post-
rocedural SM rates of 11.5% after paclitaxel-eluting stent
10) and 17.9% to 25% after SES implantation (18,19) and
2.5% after zotarolimus-eluting stent implantation were
eported (20). Although the angiographic results of our
tudy were comparable to these studies, the higher rate of
cute SM may be related to the presence of thrombus in
TEMI patients, to differences in lesion characteristics
e.g., stable vs. unstable lesions), or dynamic changes in
essel dimension after restoration of flow and stent implan-
ation. Independent predictors of acute SM were a larger
essel reference diameter and a lower maximum balloon
ressure suggesting that stents in larger vessels were more
ften underexpanded and that acute SM in this study partly
ould have been avoided by using larger balloons and higher
ressures (21). Stent underexpansion is common after
ngiography-guided stent implantation as has been demon-
trated in several studies applying IVUS-guided implanta-
ion techniques (13,22). However, a correlation of SM with
essel diameters has, as far as we know, not been reported
idual SM Sites
(SM) sites are categorized as resolved, persistent, or acquired SM. Delta (∆)
tes (resolved and persistent) are located above the x axis, indicating an
-up period. Acquired SM sites are very rare after BMS implantation. (B) SES:
persistent SM sites. Acquired SM sites are mostly located around the posi-
he P&M CSA remains virtually unchanged) is the mechanism of development
A, while the EEM CSA remains virtually unchanged) plays a role.l Indiv
sition
SM si
follow
most
hile tefore. As stent underexpansion has been related to stent
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199hrombosis and restenosis, efforts should be directed to
btain optimal expansion (23,24).
redictors of late and acquired SM. Late SM was observed
n 37.5% of the patients after SES implantation and 12.5%
fter BMS implantation. These figures are comparable with
ndings of other studies reporting a 31.8% late SM rate
fter SES implantation (11) and 11.5% after BMS implan-
ation (25). In both studies, stent implantation in STEMI
atients was an independent predictor of late SM, which
nderlines the potential risk of SM in this group of patients.
he only factor related to a lower late SM rate after SES
mplantation was diabetes mellitus, a known subgroup of
atients demonstrating more neointimal growth as com-
ared with nondiabetic patients. Poor glycemic control has
een associated with diminished efficacy of sirolimus on
mooth muscle cell proliferation, which may explain the
bsence of late SM (26). After BMS implantation, larger
essel diameter and lower maximum balloon pressure were
ndependent predictors of late SM. Late SM after BMS
mplantation seems therefore avoidable in the majority of
esions by more-aggressive implantation techniques, as dis-
ussed earlier. As diabetes mellitus in BMS patients was
ssociated with a significant restenosis rate, the role of
iabetes in late SM could not be studied. Although avoid-
nce of stent underexpansion may lower the risk of late SM
fter SES implantation by reducing the rate of persistent
Figure 3. Mechanism of Change in Lumen CSA During the Follow-Up Period
(A) BMS; (B) SES. Delta (∆) denotes change (follow-up minus post-procedure).
P&M CSA, which is positive in the majority of sites. Most likely this is due to n
change of the lumen CSA. (B) SES: Change of the lumen CSA is mainly caused
(above x axis). The P&M CSA remains virtually unchanged in most SM sites. So
in part to resolution of thrombus behind the stent. Abbreviations as in FigureM, it is unknown whether a more aggressive implantation rechnique will lower or increase the rate of acquired SM in
ES patients.
echanisms of SM. As demonstrated with IVUS, the dom-
nant mechanism of lumen change at SM sites during the
ollow-up period was vessel remodeling after SES implan-
ation and changes in plaque burden after BMS implanta-
ion (although vessel remodeling occurred also after BMS
mplantation) (27,28). Of interest in SES patients, vessel
emodeling was found at SM sites with lumen increase and
M sites with lumen decrease. These findings emphasize
hat the main effect of SES is inhibition of neointimal
rowth. Moreover, it suggests that there is a patient- or
esion site-dependent sensitivity for vessel remodeling, re-
ulting in disappearance, persistence, or appearance of SM.
n this study, the only patient-dependent protective factor
as diabetes mellitus as discussed earlier, which was also
eported by others (10). A patient-dependent factor that has
een associated with acquired SM due to positive remod-
ling is a hypersensitivity reaction to the polymer coating of
ES (29). Induction of apoptosis by sirolimus may also play
role in remodeling after SES implantation, especially at
ites of severe vessel damage during implantation (30,31).
Compared with acute SM sites associated with SES
mplantation, persistent SM sites were associated with
arger LBS CSA, arc, and length. After BMS implantation,
he LBS was only deeper compared with the LBS at
S: Changes of the lumen CSA are predominantly determined by changes in
al growth. Clearly, remodeling (mostly negative) plays a small role in
modeling after SES implantation, either negative (below x axis) or positive
sites demonstrate a clear reduction in P&M CSA, which may be due at least(A) BM
eointim
by re
me SMesolved SM sites. These findings indicate that after SES or
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200MS implantation, disappearance of acute SM cannot be
xpected if the SM site is too large or too deep. After SES
mplantation, 55% of the acute SM sites persisted. In line
ith these observations, Hong et al. (11) even reported a
00% persistence rate of acute SM after SES implantation.
As suggested by others (11), a minority of lesions (16%)
ctually showed plaque reduction as a mechanism of ac-
uired SM after SES implantation. Most likely, plaque
eduction is due to thrombus resolution, because these sites
ould be characterized by huge amounts of plaque burden
ith noncalcified plaque. Because it is virtually impossible
Figure 4. Examples of the Mechanism of Resolved and Acquired SM
The green circle indicates the EEM and the red circle the lumen contour.
Delta (∆) denotes change (follow-up minus post-procedure). (A) Resolved
proximal edge SM due to increase of plaque burden and some negative
remodeling. (Stent CSA: 10.7 mm2, lumen behind stent [LBS] CSA: 5.7 mm2,
∆EEM CSA: 2.1 mm2, ∆P&M CSA: 4.9 mm2, ∆lumen CSA: 7.0 mm2). (B)
Acquired body SM because of positive remodeling. (Stent CSA: 6.1 mm2,
LBS CSA: 7.0 mm2, ∆EEM CSA: 7.1 mm2, ∆P&M CSA: 0.1 mm2, ∆lumen CSA:
7.0 mm2). (C) Acquired body SM because of plaque reduction. (Stent CSA:
8.6 mm2, LBS CSA: 3.3 mm2, ∆EEM CSA: 0.2 mm2, ∆P&M CSA: 3.2 mm2,
∆lumen CSA: 3.3 mm2). Abbreviations as in Figure 2.o discriminate between atherosclerotic plaque and throm-us using IVUS (especially behind stent struts), definite
onclusions about the mechanism of development of SM in
ites demonstrating a reduction in plaque burden cannot be
rawn. Plaque reduction may also be the result of reduction
n atherosclerotic plaque due to medication started after the
yocardial infarction (e.g., statin therapy).
linical outcome. Although both acute and late SM were
requently observed, stent thrombosis did not occur. How-
ver, aspirin was prescribed indefinitely and clopidogrel was
rescribed for 12 months. Because late SES stent throm-
osis is mainly associated with discontinuation of antiplate-
et therapy, events may be expected beyond 12 months
1,2,4).
tudy limitations. The MISSION! Intervention Study was
rimarily an angiographic study focusing on angiographic
nd points. Nevertheless, this large study also intended to
valuate the mechanisms of acute and late SM by IVUS in
TEMI patients, making the analyses reasonable and reli-
ble. Moreover, baseline characteristics between SES and
MS patients were comparable, allowing a reliable compar-
son between both types of stents.
onclusions
cute SM is frequently observed after both SES and BMS
mplantation in STEMI patients. Late SM is rare after
MS and seems to be related to stent underexpansion in
ost patients. After SES implantation, late SM is common
ue to either persistence of acute SM or development of
cquired SM. Positive vessel remodeling is the cause of
cquired SM in most SES patients; however, in a minority
f lesions plaque reduction causes late SM.
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